IceCure Medical (NASDAQ:ICCM – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
Profitability
This table compares IceCure Medical and Icon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -441.60% | -211.73% | -119.13% |
| Icon | 5.98% | 9.50% | 5.40% |
Institutional and Insider Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 44.0% of Icon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.57 million | 3.17 | -$15.06 million | ($0.24) | -0.58 |
| Icon | $8.25 billion | 1.41 | $229.34 million | $6.16 | 23.31 |
Icon has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Icon has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for IceCure Medical and Icon, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 3 | 0 | 2.40 |
| Icon | 2 | 8 | 8 | 0 | 2.33 |
IceCure Medical currently has a consensus price target of $2.09, indicating a potential upside of 1,403.60%. Icon has a consensus price target of $156.44, indicating a potential upside of 8.92%. Given IceCure Medical’s stronger consensus rating and higher possible upside, equities analysts plainly believe IceCure Medical is more favorable than Icon.
Summary
Icon beats IceCure Medical on 11 of the 14 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Icon
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
